Jade Biosciences Announces Upcoming Clinical Trial for JADE101 in IgA Nephropathy Following Promising Preclinical Data

Reuters

2025/06/09

<a href="https://laohu8.com/S/JBIO">Jade Biosciences</a> Announces Upcoming Clinical Trial for JADE101 in IgA Nephropathy Following Promising Preclinical Data

Jade Biosciences Inc., a biotechnology company specializing in therapies for autoimmune diseases, announced plans to initiate a clinical study of its anti-APRIL monoclonal antibody, JADE101, in healthy volunteers in the latter half of 2025. This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and biomarker suppression of JADE101, specifically targeting APRIL and IgA. Interim results from this study are expected in the first half of 2026, which will aid in determining appropriate dosing for future studies in patients with IgA nephropathy (IgAN). Preclinical data, presented at the 62nd European Renal Association Congress, highlighted JADE101's potential for best-in-class efficacy with convenient dosing intervals. A conference call and webcast regarding these developments were held on June 9, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9465195-en) on June 09, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2542408386"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542408386\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2542408386?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-09 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542408386","market":"nz","top_or_hot":-1,"title":"Jade Biosciences Announces Upcoming Clinical Trial for JADE101 in IgA Nephropathy Following Promising Preclinical Data","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/JBIO\">Jade Biosciences</a> Announces Upcoming Clinical Trial for JADE101 in IgA Nephropathy Following Promising Preclinical Data\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jade Biosciences Inc., a biotechnology company specializing in therapies for autoimmune diseases, announced plans to initiate a clinical study of its anti-APRIL monoclonal antibody, JADE101, in healthy volunteers in the latter half of 2025. This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and biomarker suppression of JADE101, specifically targeting APRIL and IgA. Interim results from this study are expected in the first half of 2026, which will aid in determining appropriate dosing for future studies in patients with IgA nephropathy (IgAN). Preclinical data, presented at the 62nd European Renal Association Congress, highlighted JADE101's potential for best-in-class efficacy with convenient dosing intervals. A conference call and webcast regarding these developments were held on June 9, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9465195-en) on June 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jade Biosciences Announces Upcoming Clinical Trial for JADE101 in IgA Nephropathy Following Promising Preclinical Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJade Biosciences Announces Upcoming Clinical Trial for JADE101 in IgA Nephropathy Following Promising Preclinical Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-09 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/JBIO\">Jade Biosciences</a> Announces Upcoming Clinical Trial for JADE101 in IgA Nephropathy Following Promising Preclinical Data\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jade Biosciences Inc., a biotechnology company specializing in therapies for autoimmune diseases, announced plans to initiate a clinical study of its anti-APRIL monoclonal antibody, JADE101, in healthy volunteers in the latter half of 2025. This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and biomarker suppression of JADE101, specifically targeting APRIL and IgA. Interim results from this study are expected in the first half of 2026, which will aid in determining appropriate dosing for future studies in patients with IgA nephropathy (IgAN). Preclinical data, presented at the 62nd European Renal Association Congress, highlighted JADE101's potential for best-in-class efficacy with convenient dosing intervals. A conference call and webcast regarding these developments were held on June 9, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9465195-en) on June 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nNDLWc4xq:1","article_id":"2542408386","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542408386","pubTimestamp":1749466838,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Jade Biosciences Inc., a biotechnology company specializing in therapies for autoimmune diseases, announced plans to initiate a clinical study of its anti-APRIL monoclonal antibody, JADE101, in healthy volunteers in the latter half of 2025. This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and biomarker suppression of JADE101, specifically targeting APRIL and IgA. Interim results from this study are expected in the first half of 2026, which will aid in determining appropriate dosing for future studies in patients with IgA nephropathy . Preclinical data, presented at the 62nd European Renal Association Congress, highlighted JADE101's potential for best-in-class efficacy with convenient dosing intervals. A conference call and webcast regarding these developments were held on June 9, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information,","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","JBIO":"Jade Biosciences","NDAQ":"纳斯达克OMX交易所","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4585":"ETF&股票定投概念","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4588":"碎股","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4539":"次新股","BK4112":"金融交易所和数据","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC"},"translate_title":"Jade Biosciences宣布即将进行JADE101治疗IgA肾病的临床试验，临床前数据令人鼓舞","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JBIO":0.9,"NDAQ":0.9},"content_text":"Jade Biosciences Announces Upcoming Clinical Trial for JADE101 in IgA Nephropathy Following Promising Preclinical Data\n    \n\n        Jade Biosciences Inc., a biotechnology company specializing in therapies for autoimmune diseases, announced plans to initiate a clinical study of its anti-APRIL monoclonal antibody, JADE101, in healthy volunteers in the latter half of 2025. This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and biomarker suppression of JADE101, specifically targeting APRIL and IgA. Interim results from this study are expected in the first half of 2026, which will aid in determining appropriate dosing for future studies in patients with IgA nephropathy (IgAN). Preclinical data, presented at the 62nd European Renal Association Congress, highlighted JADE101's potential for best-in-class efficacy with convenient dosing intervals. A conference call and webcast regarding these developments were held on June 9, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9465195-en) on June 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}